S
CRL icon

SignatureFD’s Charles River Laboratories CRL Stock Holding History

SignatureFD’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$225K Sell
1,305
-35
-3% -$6.49K ﹤0.01% 939
2025
Q4 		$267K Sell
1,340
-2
-0.1% -$363 ﹤0.01% 831
2025
Q3 		$210K Sell
1,342
-15
-1% -$2.38K ﹤0.01% 937
2025
Q2 		$206K Buy
1,357
+57
+4% +$7.6K ﹤0.01% 904
2025
Q1 		$196K Buy
1,300
+275
+27% +$46.1K ﹤0.01% 894
2024
Q4 		$189K Buy
1,025
+9
+0.9% +$1.73K ﹤0.01% 899
2024
Q3 		$200K Sell
1,016
-19
-2% -$3.95K ﹤0.01% 861
2024
Q2 		$214K Sell
1,035
-10
-1% -$2.27K ﹤0.01% 791
2024
Q1 		$283K Buy
1,045
+15
+1% +$3.58K 0.01% 699
2023
Q4 		$243K Sell
1,030
-343
-25% -$67.5K 0.01% 719
2023
Q3 		$269K Buy
1,373
+398
+41% +$81.7K 0.01% 629
2023
Q2 		$205K Sell
975
-293
-23% -$58.3K 0.01% 749
2023
Q1 		$256K Sell
1,268
-110
-8% -$24.9K 0.01% 636
2022
Q4 		$300K Buy
1,378
+218
+19% +$47.6K 0.01% 560
2022
Q3 		$228K Sell
1,160
-93
-7% -$20.1K 0.01% 630
2022
Q2 		$268K Buy
1,253
+9
+0.7% +$2.2K 0.01% 582
2022
Q1 		$353K Buy
1,244
+88
+8% +$27.1K 0.01% 522
2021
Q4 		$436K Sell
1,156
-229
-17% -$89K 0.01% 440
2021
Q3 		$572K Buy
1,385
+230
+20% +$95.5K 0.02% 326
2021
Q2 		$427K Sell
1,155
-4
-0.3% -$1.34K 0.02% 406
2021
Q1 		$336K Buy
1,159
+98
+9% +$27.2K 0.01% 415
2020
Q4 		$265K Sell
1,061
-1,002
-49% -$239K 0.01% 446
2020
Q3 		$467K Buy
2,063
+84
+4% +$17.4K 0.03% 251
2020
Q2 		$345K Buy
1,979
+985
+99% +$157K 0.02% 299
2020
Q1 		$125K Buy
994
+21
+2% +$3.15K 0.01% 559
2019
Q4 		$149K Buy
973
+24
+3% +$3.32K 0.01% 567
2019
Q3 		$126K Sell
949
-5
-0.5% -$670 0.01% 562
2019
Q2 		$135K Sell
954
-71
-7% -$9.63K 0.01% 518
2019
Q1 		$149K Sell
1,025
-28
-3% -$3.68K 0.01% 485
2018
Q4 		$119K Buy
1,053
+70
+7% +$8.76K 0.01% 519
2018
Q3 		$132K Hold
983
– – 0.01% 539
2018
Q2 		$110K Hold
983
– – 0.01% 582
2018
Q1 		$105K Buy
+983
New +$106K 0.01% 514
2016
Q4 		– Sell
-20
Closed -$2K – 458
2016
Q3 		$2K Hold
20
– – ﹤0.01% 1409
2016
Q2 		$2K Hold
20
– – ﹤0.01% 1220
2016
Q1 		$2K Hold
20
– – ﹤0.01% 1154
2015
Q4 		$2K Buy
+20
New +$1.44K ﹤0.01% 1076
2014
Q2 		– Sell
-955
Closed -$58K – 899
2014
Q1 		$58K Hold
955
– – 0.02% 181
2013
Q4 		$51K Hold
955
– – 0.02% 216
2013
Q3 		$44K Buy
+955
New +$43.8K 0.02% 216

Other funds holding CRL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

SignatureFD's CRL Position: Q1 2026 in Review

SignatureFD reduced its Charles River Laboratories (CRL) stake by 2.6% in Q1 2026, selling an estimated $6.49K and leaving 1,305 shares worth $225K. The position accounts for ﹤0.01% of the portfolio, ranked #939.

SignatureFD first reported a position in CRL in Q3 2013 and has held it in 40 quarters since. The position peaked at $572K in Q3 2021. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • SignatureFD held 1,305 shares of Charles River Laboratories worth $225K as of Q1 2026.
  • SignatureFD sold 35 Charles River Laboratories shares in Q1 2026, an estimated $6.49K.
  • Charles River Laboratories made up ﹤0.01% of SignatureFD's portfolio in Q1 2026, its #939 holding.
  • SignatureFD first reported a position in Charles River Laboratories in Q3 2013 and has held it in 40 quarters since.
  • SignatureFD's Charles River Laboratories position peaked at $572K in Q3 2021.
  • 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on SignatureFD's 13F filing for Q1 2026, filed 7 Apr 2026.